2-(3-tert-butoxycarbonylaminopropoxy)-4-(morpholin-4-yl)benzoic acid | 852370-39-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 2-(3-tert-butoxycarbonylaminopropoxy)-4-(morpholin-4-yl)benzoic acid
• 英文别名: 2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propoxy]-4-morpholin-4-ylbenzoic acid
• CAS: 852370-39-9
• 化学式: C₁₉H₂₈N₂O₆
• 分子量: 380.441
• InChiKey: FCDWOZLVDHSDAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  97.3
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-(3-tert-butoxycarbonylaminopropoxy)-4-(morpholin-4-yl)benzoic acid 在 吡啶 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 生成 2-[2-(3-tert-butoxycarbonylaminopropoxy)-4-(4-morpholinyl)benzoylamino]-N-(5-chloropyridin-2-yl)benzamide
  参考文献：
  名称：

  Anthranilamide inhibitors of factor Xa

  摘要：

  SAR about the B-ring of a series of N-2-aroyl anthranilamide factor Xa (tXa) inhibitors is described. B-ring o-aminoalkylether and B-ring p-amine probes of the S1' and S4 sites, respectively, afforded picomolar fXa inhibitors that performed well in in vitro anticoagulation assays. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.06.051
• 作为产物：
  描述：

  2,4-二氟苯甲酸乙酯 在 lithium hydroxide 、 potassium tert-butylate 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 生成 2-(3-tert-butoxycarbonylaminopropoxy)-4-(morpholin-4-yl)benzoic acid
  参考文献：
  名称：

  Anthranilamide inhibitors of factor Xa

  摘要：

  SAR about the B-ring of a series of N-2-aroyl anthranilamide factor Xa (tXa) inhibitors is described. B-ring o-aminoalkylether and B-ring p-amine probes of the S1' and S4 sites, respectively, afforded picomolar fXa inhibitors that performed well in in vitro anticoagulation assays. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.06.051

文献信息

• AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS
  申请人：Argade Ankush Baburao

  公开号：US20090227566A1

  公开（公告）日：2009-09-10

  This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. An example of a compound of formula (I) is (a).

  本发明涉及公式(I)的化合物(或其药学上可接受的盐或前药)、其制药组合物以及其作为Xa因子和/或凝血酶抑制剂的用途，以及其制备过程和中间体。公式(I)的化合物的一个例子是(a)。
• Antithrombotic aromatic ethers
  申请人：Franciskovich Bernard Jeffry

  公开号：US20070027185A1

  公开（公告）日：2007-02-01

  This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.

  本申请涉及化合物I的配方（或其前药或其药学上可接受的盐或前药的药物组成物），如此处所定义，其用作因子Xa和/或凝血酶的抑制剂，以及其制备过程和其中间体。
• Aromatic ether derivatives useful as thrombin inhibitors
  申请人：Eli Lilly and Company

  公开号：US07700628B2

  公开（公告）日：2010-04-20

  This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. An example of a compound of formula (I) is (a).

  本申请涉及公式（I）的化合物（或其药学上可接受的盐或前药）、其制药组合物以及其作为因子Xa和/或凝血酶抑制剂的用途，以及其制备方法和中间体。公式（I）的一种化合物示例如（a）。
• [EN] ANTITHROMBOTIC AROMATIC ETHERS<br/>[FR] ETHERS AROMATIQUES ANTITHROMBOTIQUES
  申请人：LILLY CO ELI

  公开号：WO2005049604A3

  公开（公告）日：2005-09-15
• ANTITHROMBOTIC AROMATIC ETHERS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1670783A2

  公开（公告）日：2006-06-21